Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The RadarInvestors Business Daily • 06/14/24
New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of TreatmentBusiness Wire • 06/14/24
Law Firms Speaking Out For The Thousands of California HIV Patients They Represent After Gilead's $40 Million Settlement Prompts Moral Reckoning for the HIV CommunityGlobeNewsWire • 06/13/24
Gilead Sciences, Inc. (GILD) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)Seeking Alpha • 06/13/24
Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNABusiness Wire • 06/06/24
Gilead's Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary CholangitisBusiness Wire • 06/05/24
Kite's Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaBusiness Wire • 06/03/24
Encouraging New Data Presented on Kite's Yescarta® for Relapsed/Refractory Central Nervous System LymphomaBusiness Wire • 06/03/24
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal CancerBusiness Wire • 06/02/24
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI CancersBusiness Wire • 06/01/24
Gilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary GoalZacks Investment Research • 05/31/24
EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024Business Wire • 05/31/24